Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Number Needed-to-Treat (NNT): is it a necessary marker of therapeutic efficiency?

Monnier L, Colette C, Bonnet F, Owens D.

Diabetes Metab. 2020 Feb 5. pii: S1262-3636(20)30023-9. doi: 10.1016/j.diabet.2020.01.004. [Epub ahead of print] No abstract available.

PMID:
32035226
2.

Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?

Monnier L, Wojtusciszyn A, Molinari N, Colette C, Renard E, Owens D.

Diabetes Care. 2020 Jan 27. pii: dc191549. doi: 10.2337/dc19-1549. [Epub ahead of print]

PMID:
31988062
3.

Outcomes of vaginal squamous cell carcinoma of patients treated with radiation therapy: a series of 37 patients from a single expert center.

Romano E, Janati S, Monnier L, Darai É, Bendifallah S, Schlienger M, Touboul E, Rivin Del Campo E, Huguet F.

Clin Transl Oncol. 2019 Dec 23. doi: 10.1007/s12094-019-02264-y. [Epub ahead of print]

PMID:
31873914
4.

Regulation of Mitochondria-Associated Membranes (MAMs) by NO/sGC/PKG Participates in the Control of Hepatic Insulin Response.

Bassot A, Chauvin MA, Bendridi N, Ji-Cao J, Vial G, Monnier L, Bartosch B, Alves A, Cottet-Rousselle C, Gouriou Y, Rieusset J, Morio B.

Cells. 2019 Oct 25;8(11). pii: E1319. doi: 10.3390/cells8111319.

5.

Calibration free continuous glucose monitoring (CGM) devices: Weighing up the benefits and limitations.

Monnier L, Colette C, Owens D.

Diabetes Metab. 2019 Sep 11:101118. doi: 10.1016/j.diabet.2019.101118. [Epub ahead of print] No abstract available.

PMID:
31520684
6.

Coelomocytes Regulate Starvation-Induced Fat Catabolism and Lifespan Extension through the Lipase LIPL-5 in Caenorhabditis elegans.

Buis A, Bellemin S, Goudeau J, Monnier L, Loiseau N, Guillou H, Aguilaniu H.

Cell Rep. 2019 Jul 23;28(4):1041-1049.e4. doi: 10.1016/j.celrep.2019.06.064.

7.
8.

Comparison of 3D conformal radiation therapy and intensity-modulated radiation therapy in patients with endometrial cancer: efficacy, safety and prognostic analysis.

Ta MH, Schernberg A, Giraud P, Monnier L, Darai É, Bendifallah S, Schlienger M, Touboul E, Orthuon A, Challand T, Huguet F, Rivin Del Campo E.

Acta Oncol. 2019 Aug;58(8):1127-1134. doi: 10.1080/0284186X.2019.1599136. Epub 2019 Apr 24.

9.

Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend.

Monnier L, Colette C, Schlienger JL, Bauduceau B, R Owens D.

Diabetes Metab. 2019 Oct;45(5):401-408. doi: 10.1016/j.diabet.2019.01.007. Epub 2019 Jan 24. Review.

PMID:
30685425
10.

Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group.

de Foucher T, Bendifallah S, Ouldamer L, Bricou A, Lavoue V, Varinot J, Canlorbe G, Carcopino X, Raimond E, Monnier L, Graesslin O, Touboul C, Collinet P, Neveu ME, Huchon C, Daraï E, Ballester M; Groupe de Recherche Francogyn, France.

Eur J Surg Oncol. 2019 Apr;45(4):659-665. doi: 10.1016/j.ejso.2018.11.014. Epub 2018 Dec 30.

PMID:
30685326
11.

Combined reversible switching of ECD and quenching of CPL with chiral fluorescent macrocycles.

Homberg A, Brun E, Zinna F, Pascal S, Górecki M, Monnier L, Besnard C, Pescitelli G, Di Bari L, Lacour J.

Chem Sci. 2018 Aug 1;9(35):7043-7052. doi: 10.1039/c8sc02935k. eCollection 2018 Sep 21.

12.

Branched-Chain Amino Acid Database Integrated in MEDIPAD Software as a Tool for Nutritional Investigation of Mediterranean Populations.

Haydar S, Paillot T, Fagot C, Cogne Y, Fountas A, Tutuncu Y, Vintila M, Tsatsoulis A, Thanh Chi P, Garandeau P, Chetea D, Badiu C, Gheorghiu M, Ylli D, Lautier C, Jarec M, Monnier L, Normand C, Šarac J, Barakat A, Missoni S, Pugeat M, Poucheret P, Hanzu F, Gomis R, Macias JM, Litvinov S, Khusnutdinova E, Poiana C, Pasquali R, Lauro D, Sesti G, Trischitta V, Abdelhak S, Zenati A, Ylli A, Satman I, Kanninen T, Rinato Y, Grigorescu F.

Nutrients. 2018 Oct 1;10(10). pii: E1392. doi: 10.3390/nu10101392.

13.

Glycaemic variability in diabetes: clinical and therapeutic implications.

Ceriello A, Monnier L, Owens D.

Lancet Diabetes Endocrinol. 2019 Mar;7(3):221-230. doi: 10.1016/S2213-8587(18)30136-0. Epub 2018 Aug 13. Review.

PMID:
30115599
14.

The application of simple metrics in the assessment of glycaemic variability.

Monnier L, Colette C, Owens DR.

Diabetes Metab. 2018 Sep;44(4):313-319. doi: 10.1016/j.diabet.2018.02.008. Epub 2018 Mar 6. Review.

PMID:
29602622
15.

Association of postprandial and fasting plasma glucose with HbA1c across the spectrum of glycaemic impairment in type 2 diabetes.

Valensi P, Husemoen LLN, Weatherall J, Monnier L.

Int J Clin Pract. 2017 Dec;71(12). doi: 10.1111/ijcp.13041. No abstract available.

16.

Pharmacological variability of insulins degludec and glargine 300U/mL: Equivalent or not?

Monnier L, Colette C.

Diabetes Metab. 2018 Feb;44(1):1-3. doi: 10.1016/j.diabet.2017.11.001. Epub 2017 Nov 14. No abstract available.

PMID:
29196025
17.

Glucose variability: Do we have to revisit the profusion of definitions to avoid confusion?

Monnier L, Colette C, Owens D.

Diabetes Metab. 2018 Mar;44(2):97-100. doi: 10.1016/j.diabet.2017.10.005. Epub 2017 Nov 16. No abstract available.

PMID:
29153486
18.

Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non).

Monnier L, Culine S, Cormier L.

Presse Med. 2017 Oct;46(10):940-947. doi: 10.1016/j.lpm.2017.03.007. Epub 2017 May 23. French.

PMID:
28549631
19.

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.

Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O.

J Pharmacol Exp Ther. 2017 Jul;362(1):186-199. doi: 10.1124/jpet.116.239665. Epub 2017 May 5.

PMID:
28476928
20.

A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.

Owens DR, Monnier L, Hanefeld M.

Diabetes Obes Metab. 2017 Dec;19(12):1645-1654. doi: 10.1111/dom.12998. Epub 2017 Jul 11. Review.

21.

Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy.

Owens DR, Monnier L, Barnett AH.

Diabetes Obes Metab. 2017 Oct;19(10):1339-1352. doi: 10.1111/dom.12977. Epub 2017 Jun 9. Review.

22.

Anoperineal disease in Hidradenitis Suppurativa : MR imaging distinction from perianal Crohn's disease.

Monnier L, Dohan A, Amara N, Zagdanski AM, Drame M, Soyer P, Hoeffel C.

Eur Radiol. 2017 Oct;27(10):4100-4109. doi: 10.1007/s00330-017-4776-1. Epub 2017 Mar 13.

PMID:
28289934
23.

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.

Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, Owens DR.

Diabetes Care. 2017 Jul;40(7):832-838. doi: 10.2337/dc16-1769. Epub 2016 Dec 30.

PMID:
28039172
24.

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

Hanefeld M, Raccah D, Monnier L.

Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):311-321. doi: 10.1080/17425255.2017.1251579. Epub 2016 Nov 3. Review.

PMID:
27776453
26.

Tailoring nutrient sequence and content to improve glucose tolerance: Why and how to do it.

Monnier L, Bonnet F, Colette C.

Diabetes Metab. 2016 Sep;42(4):211-4. doi: 10.1016/j.diabet.2016.04.003. Epub 2016 May 13. No abstract available.

PMID:
27184768
27.

Two phases of aging separated by the Smurf transition as a public path to death.

Dambroise E, Monnier L, Ruisheng L, Aguilaniu H, Joly JS, Tricoire H, Rera M.

Sci Rep. 2016 Mar 22;6:23523. doi: 10.1038/srep23523.

28.

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials.

Hanefeld M, Monnier L, Schnell O, Owens D.

Diabetes Ther. 2016 Jun;7(2):187-201. doi: 10.1007/s13300-016-0153-3. Epub 2016 Feb 10. Review.

29.

[Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].

Monnier L, Touboul E, Daraï E, Lefranc JP, Lauratet B, Ballester M, Huguet F.

Bull Cancer. 2016 Feb;103(2):164-72. doi: 10.1016/j.bulcan.2015.11.010. Epub 2016 Jan 25. French.

PMID:
26822905
30.

Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Monnier L, Colette C, Dejager S, Owens DR.

Rev Endocr Metab Disord. 2016 Mar;17(1):91-101. doi: 10.1007/s11154-016-9325-8. Review.

PMID:
26803295
31.

Postprandial and basal hyperglycaemia in type 2 diabetes: Contributions to overall glucose exposure and diabetic complications.

Monnier L, Colette C.

Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S9-6S15. doi: 10.1016/S1262-3636(16)30003-9.

PMID:
26774019
32.

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation.

Monnier L, Owens DR, Bolli GB.

Diabetes Metab. 2016 Apr;42(2):77-9. doi: 10.1016/j.diabet.2015.11.005. Epub 2015 Dec 10. No abstract available.

PMID:
26688145
33.

Ramadan and diabetes: What we see, learn and understand from continuous glucose monitoring.

Monnier L, El Azrak A, Lessan N, Rochd D, Colette C, Bonnet F.

Diabetes Metab. 2015 Dec;41(6):456-62. doi: 10.1016/j.diabet.2015.09.002. Epub 2015 Oct 23. Review.

PMID:
26476619
34.

Association of HbA1c variability with atherosclerosis in diabetes: simple marker, risk factor or statistical bias?

Monnier L, Colette C.

J Diabetes Complications. 2015 Aug;29(6):745-6. doi: 10.1016/j.jdiacomp.2015.05.002. Epub 2015 May 7. No abstract available.

PMID:
26082425
35.

[Ductal carcinoma in situ treated with radiation therapy and additional boost].

Geiss R, Cabel L, Touboul E, Lefranc JP, Daraï É, Lauratet B, Monnier L, Haberer-Guillerm S, Deluen F, Schlienger M, Huguet F.

Cancer Radiother. 2015 May;19(3):175-9. doi: 10.1016/j.canrad.2015.01.002. Epub 2015 Apr 25. French.

PMID:
25921619
36.

Using the respective contributions of postprandial and basal glucose for tailoring treatments in type 2 diabetes.

Monnier L, Colette C.

Diabetes Metab. 2015 Jun;41(3):179-82. doi: 10.1016/j.diabet.2015.03.004. Epub 2015 Apr 17. No abstract available.

PMID:
25900889
37.

FTY720 Phosphate Activates Sphingosine-1-Phosphate Receptor 2 and Selectively Couples to Gα12/13/Rho/ROCK to Induce Myofibroblast Contraction.

Sobel K, Monnier L, Menyhart K, Bolinger M, Studer R, Nayler O, Gatfield J.

Mol Pharmacol. 2015 Jun;87(6):916-27. doi: 10.1124/mol.114.097261. Epub 2015 Mar 11.

PMID:
25762025
38.

"Mild dysglycemia" in type 2 diabetes: to be neglected or not?

Monnier L, Colette C, Dejager S, Owens DR.

J Diabetes Complications. 2015 Apr;29(3):451-8. doi: 10.1016/j.jdiacomp.2014.12.004. Epub 2014 Dec 12. Review.

PMID:
25572605
39.

New insights on glucose homoeostasis during Ramadan.

Monnier L, Bonnet F, Colette C.

Diabetes Metab. 2015 Feb;41(1):1-4. doi: 10.1016/j.diabet.2014.11.005. Epub 2014 Dec 15. No abstract available.

PMID:
25523359
41.

The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Metab. 2015 Apr;41(2):132-7. doi: 10.1016/j.diabet.2014.10.002. Epub 2014 Nov 6.

PMID:
25457475
42.

Response to comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062.

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Care. 2014 Jul;37(7):e163. doi: 10.2337/dc14-0609. No abstract available.

PMID:
24963117
43.

Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trials.

Schnell O, Hanefeld M, Monnier L.

J Diabetes Sci Technol. 2014 May;8(3):609-14. doi: 10.1177/1932296814528134. Epub 2014 Apr 2.

44.

Glycaemic variability and ambient hyperglycaemia: how and when are they linked?

Monnier L, Colette C.

Diabetes Metab. 2014 Sep;40(4):237-40. doi: 10.1016/j.diabet.2014.04.003. Epub 2014 May 19. No abstract available.

PMID:
24852510
45.

Residual dysglycemia when at target HbA(1c) of 7% (53mmol/mol) in persons with type 2 diabetes.

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Res Clin Pract. 2014 Jun;104(3):370-5. doi: 10.1016/j.diabres.2014.03.012. Epub 2014 Mar 28.

PMID:
24735710
46.

Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.

Gatfield J, Monnier L, Studer R, Bolli MH, Steiner B, Nayler O.

Cell Signal. 2014 Jul;26(7):1576-88. doi: 10.1016/j.cellsig.2014.03.029. Epub 2014 Apr 2.

PMID:
24704119
47.

[Isolated pelvic recurrences of cervical carcinoma treated with salvage chemoradiotherapy].

Besson N, Touboul E, Daraï É, Lefranc JP, Monnier L, Schlienger M, Huguet F.

Cancer Radiother. 2014 Mar;18(2):83-8. doi: 10.1016/j.canrad.2013.11.010. Epub 2014 Jan 24. French.

PMID:
24462252
48.

Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?

Monnier L, Colette C, Dejager S, Owens D.

Diabetes Care. 2013 Dec;36(12):4057-62. doi: 10.2337/dc12-2127. Epub 2013 Oct 29.

49.

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.

Owens DR, Monnier L, Bolli GB.

Diabetes Metab. 2013 Dec;39(6):485-96. doi: 10.1016/j.diabet.2013.09.004. Epub 2013 Oct 22. Review.

PMID:
24156868
50.

Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend?

Monnier L, Colette C, Owens D.

Diabetes Metab. 2013 Dec;39(6):468-76. doi: 10.1016/j.diabet.2013.09.003. Epub 2013 Oct 17. Review.

PMID:
24139826

Supplemental Content

Loading ...
Support Center